Hepatitis C Cont…(3)

(Post 1) (Post 2) (Post 3)

Medivir is also developing Hepatitis C drug (TMC435) with Tibotec Pharmaceuticals. Medivir announced positive interim Phase IIb data on efficacy of TMC 435.


TMC435 is a once daily protease inhibitor jointly developed by Medivir and Tibotec Pharmaceuticals to treat hepatitis C virus infections. TMC435 is currently being studied in three phase 2b clinical trials, TMC435-C205, TMC435-C206 and TMC435-C215, in G1 treatment-naive and in G1 patients that failed previous IFN-based treatment. TMC435 is planned to enter phase 3 studies early 2011.


About Guna

Interested to learn things around me
This entry was posted in Drug developments & targets. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s